Minerva Neurosciences Preps Phase 3 Trial for Schizophrenia's Negative Symptoms
Event summary
- Minerva Neurosciences to host virtual KOL event on February 3, 2026, to discuss roluperidone for schizophrenia's negative symptoms.
- Phase 3 trial for roluperidone expected to start in 2026, aligning with FDA considerations.
- Event features Gregory Strauss, PhD, and Brian Kirkpatrick, MD, MSPH, as key opinion leaders.
- Negative symptoms of schizophrenia affect 50-60% of patients and lack FDA-approved treatments.
The big picture
Minerva Neurosciences is positioning itself at the forefront of addressing a critical unmet need in schizophrenia treatment—the negative symptoms that current antipsychotics fail to alleviate. With the FDA's recent public meeting on optimal trial approaches and Minerva's planned Phase 3 trial, the company is strategically aligning with regulatory expectations to potentially bring the first approved treatment for these debilitating symptoms to market. The event underscores the growing focus on precision treatments in neuroscience, where targeted therapies for specific symptom clusters could redefine patient care and market dynamics.
What we're watching
- Regulatory Alignment
- Whether Minerva's novel Phase 3 trial protocol can successfully address FDA's regulatory challenges for negative symptom treatments.
- Clinical Trial Execution
- The pace at which Minerva can enroll and complete the Phase 3 trial, given the complexity of assessing negative symptoms.
- Market Opportunity
- How the potential approval of roluperidone could reshape the treatment landscape for schizophrenia's negative symptoms.
Related topics